Evidence map›Paper›PMID 36717474›Full record

ArticleEuropean radiology experimental2023

A novel method for predicting hepatocellular carcinoma response to chemoembolization using an intraprocedural CT hepatic arteriography-based enhancement mapping: a proof-of-concept analysis.

Ryosuke Taiji, Yuan-Mao Lin, Gouthami Chintalapani, Ethan Y Lin, Steven Y Huang, Armeen Mahvash, Rony Avritscher, Chien-An Liu, Rheun-Chuan Lee, Vivian Resende and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European radiology experimental, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Ryosuke TaijiDivision of Diagnostic Imaging, Department of Interventional Radiology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.
Yuan-Mao LinDivision of Diagnostic Imaging, Department of Interventional Radiology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.
Gouthami ChintalapaniSiemens Medical Solutions USA Inc, 501 North Barrington Road, Hoffman Estates, IL, 60192, USA.
Ethan Y LinDivision of Diagnostic Imaging, Department of Interventional Radiology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.
Steven Y HuangDivision of Diagnostic Imaging, Department of Interventional Radiology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.
Armeen MahvashDivision of Diagnostic Imaging, Department of Interventional Radiology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.
Rony AvritscherDivision of Diagnostic Imaging, Department of Interventional Radiology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.
Chien-An LiuDepartment of Radiology, Taipei Veterans General Hospital, Taipei, 112, Taiwan.
Rheun-Chuan LeeDepartment of Radiology, Taipei Veterans General Hospital, Taipei, 112, Taiwan.
Vivian ResendeDepartment of Surgery, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil.
Hideyuki NishiofukuDepartment of Radiology and Nuclear Medicine, Nara Medical University, Kashihara, Nara, 634-8521, Japan.
Toshihiro TanakaDepartment of Radiology and Nuclear Medicine, Nara Medical University, Kashihara, Nara, 634-8521, Japan.
Kimihiko KichikawaDepartment of Radiology and Nuclear Medicine, Nara Medical University, Kashihara, Nara, 634-8521, Japan.
Ernst KlotzSiemens Healthineers, Siemensstraße 3, 91301, Forchheim, Germany.
Sanjay GuptaDivision of Diagnostic Imaging, Department of Interventional Radiology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.
Bruno C OdisioDivision of Diagnostic Imaging, Department of Interventional Radiology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA. BCOdisio@mdanderson.org.ORCID 0000-0002-1771-8233

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTo evaluate the feasibility of a novel approach for predicting hepatocellular carcinoma (HCC) response to drug-eluting beads transarterial chemoembolization (DEB-TACE) using computed tomography hepatic arteriography enhancement mapping (CTHA-EM) method.

methodsThis three-institution retrospective study included 29 patients with 46 HCCs treated with DEB-TACE between 2017 and 2020. Pre- and posttreatment CTHA-EM images were generated using a prototype deformable registration and subtraction software. Relative tumor enhancement (T

resultsCTHA-EM showed residual enhancement in 18/46 (39.1%) and non-residual enhancement in 28/46 (60.9%) HCCs, with significant differences on T

conclusionCTHA-EM method was highly accurate in predicting initial HCC response to DEB-TACE and identifying feeding arteries to the areas of residual arterial enhancement.

Indexed as

Carcinoma, HepatocellularChemoembolization, TherapeuticLiver NeoplasmsAngiographyHumansRetrospective StudiesTomography, X-Ray ComputedTreatment OutcomeCarcinoma (hepatocellular)Chemoembolization (therapeutic)Computed tomography angiographyCone-beam computed tomographyMicrospheres

Identifiers

PMID36717474
PMCPMC9886747

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.